课题基金 / 基金详情

NIAID PRECLINICAL DEVELOPMENT SUPPORT - PRODUCTION OF HCMV-TR3∆PP71 HIVGAG FOR CLINICAL TRIALS

NIAID PRECLINICAL DEVELOPMENT SUPPORT - PRODUCTION OF HCMV-TR3∆PP71 HIVGAG FOR CLINICAL TRIALS
NIAID 临床前开发支持 - 生产用于临床试验的 HCMV-TR3™PP71 HIVGAG
批准号:
9923498
负责人:
NANCY LIN
金额:
$12.57万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-26 至 2021-12-31

项目摘要

项目成果

NANCY LIN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This contract will provide NIAID with a broad and flexible range of nontraditional, proactive and developmentally-oriented capabilities to provide preclinical development support for promising products when such products emerge from investigator-initiated research studies. These capabilities will allow NIAID to more rapidly and efficiently close development and production gaps. The Contractor shall assist NIAID staff in providing all support needed for small-scale production, preclinical testing and documentation leading to Investigational New Drug (IND) submission for Phase I, II, and III clinical testing. Activities include: -Process Development and Production of candidate HIV vaccines, microbicides or non-vaccines HIV prevention modalities -Safety, Immunogenicity and Spectrum of Activity Testing of candidate HIV vaccines, microbicides or non-vaccines HIV prevention modalities consistent with relevant FDA guidelines -Regulatory Documentation-obtain and compile non-clinical data, Investigator's Brochure, and/or final product trail protocol appropriate for submission to CBER or CDER, FDA (for an IND application) or other non-US regulatory authorities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NIAID PRECLINICAL DEVELOPMENT SUPPORT - TOXICITY TESTING FOR CH505 T/F GP120 PROTEIN
NIAID PRECLINICAL DEVELOPMENT SUPPORT - PRODUCTION OF HIV-1 gp120 PROTEIN
NIAID PRECLINICAL DEVELOPMENT SUPPORT - PRODUCTION OF MHRP GP145 CLADE C PROTEIN
NIAID PRECLINICAL DEVELOPMENT SUPPORT - PRODUCTION OF MHRP GP145 CLADE C PROTEIN
海外基金